AstraZeneca’s 2 mg Bydureon Pen has received FDA approval as an adjunct to diet and exercise for control of blood sugar in patients with type 2 diabetes, the drugmaker said Monday. The pen, which follows a single-dose tray approved in 2012, will be available in the U.S. later this year.
The Bydureon Pen (exenatide extended release for injectable suspension) is administered once per week via microsphere technology, replacing an older system that requires a transfer between a vial and a syringe but providing the same extended-release dose of exenatide, the company says. — Lena Freund
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.